Ono Pharma's eyes on IDAC's anti-CD4 antibody

24 May 2016

Japan’s Ono Pharmaceutical (TYO: 4528) has signed an agreement with IDAC Theranostics, a Tokyo-based research company focusing on treatments for cancers and inflammatory diseases, to make sure it will access IDAC’s anti-CD4 antibody IT1208 in the first place.

The agreement allows Ono, based in Osaka, to be the exclusive company to evaluate the result of the Phase I trials of IT1208. If the result is positive, Ono will be the only company to negotiate an in-licensing deal, reports The Pharma Letter’s local correspondent Wang Fangqing

A humanized antibody targeting CD4, IT1208 uses potelligent technology from Kyowa Hakko Kirin (TYO: 4151) to have an enhanced antibody dependent cellular cytotoxicity. It is currently recruiting in Japan for the Phase I studies, which will be completed by IDAC, according to the agreement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK